( Recommended in SAKAL NEWS PAPER. Arthvishwa ) : 22th June 2009 
Notables Observes :
Notables Observes :
- Cipla pioneered Bulk Drug manufacturing in the country, which truly laid the foundation for the Pharmaceutical industry in India. Over the years our commitment to heal, protect and enrich lives has only grown, and so have our capabilities.
- Cipla's products & services are categorized into Prescription, Animal Products, OTC, Bulk Drugs, Flavours & Fragrances, Agrochemicals and Technology.
- Cipla has 31 world-class manufacturing facilities spread across the country, with dedicated plants for Oncology products, Hormones, Inhalers, Carbapenems, and Cephlosporins, among others. They more than meet the stringent international standards, such as that of US FDA, MHRA–UK, TGA Australia, BFarm–Germany MCC–South Africa, WHO, TPD- Canada.
- Cipla produces one of the widest range of products and dosage forms in the world today, everything from metered-dose inhalers, pre-filled syringes, trans-dermal spray patches, lyophilized injections, nasal sprays, medical devices, and thermolabile foams. Whether it is constantly extending our product range or consistently introducing innovations, the mission is always to make the life of the patient better.
Share Holding Pattern :
- Promoter : 39.38 %
- Public : 59.56 %
Financial Highlights :
- The Company has posted a net profit after tax of Rs 767.83 Crore for the year ended March 31, 2009 as compared to Rs 701.43 Crore for the year ended March 31, 2008.
- Total Income has increased from Rs 4271.13 Crore for the year ended March 31, 2008 to Rs 5338.37 Crore for the year ended March 31, 2009.
Technical Overview :
The stock On Weekly Chart has given a "Flag Pattern" Breakout,with huge volumes indicating the trend reversal and beginning of a uptrend. The stock is recomended to buy at cmp Rs265.45.
Support Levels :
- Support 1 : 258
- Support 2 : 239
Stop Loss : 221 on closing basis.
Targets :
- Targets : 304
- Target 2 : 325
- Target 3 : 339
- Target 4 : 356
Period : 5 to 6 months.